Endocrine Gland Neoplasms
12
3
3
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Establishment of a Tumor Bank for Tissue Samples
Establishment of a Tumor Bank for Blood Samples
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
A Study of Trabectedin in Patients With Advanced Ovarian Cancer